PFEPfizer
Is the business good?
The checks split: 5 of 9 health tests passed and returns not propped up by debt.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
A balanced mix of margins, efficiency, and leverage. ROE 8% = margin × turnover × leverage.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is PFE?
Pfizer keeps 6.8% of every revenue dollar as profit after everything, against 18% for the median Drug Manufacturers - General name.
Net margin · Drug Manufacturers - General median 18% · 12 months to Q2 2026
- Share count, year on year
- −0.12%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 17%
R&D as % of revenue
- Gross margin
- 73%
Gross margin
Details›
- Gross margin12 months to Q2 2026
- 73%
- Net margin12 months to Q2 2026
- 6.8%
- Free cash flow margin
- 17%
- R&D as % of revenue
- 17%
- Revenue, trailing twelve months
- $63.7B
- Free cash flow, trailing twelve months
- $11.0B
- Net income, trailing twelve months
- $4.33B
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, General
The closest names by size in the same industry